Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2007

Bind Receives $2M to Advance Platform for Targeted Nanoparticle Engineering

  • Bind Biosciences was awarded a three-year $2 million grant to further develop its platform for high-throughput formulation and selection of targeted nanoparticles. The company’s technology has the potential to create a novel class of therapeutics based on optimally engineered targeted polymeric nanoparticles, points out Glenn Batchelder, president and CEO.

    The funding was received from the National Institute of Standards and Technology (NIST) under its Advanced Technology Program (ATP).  “The ATP funding will accelerate industrialization of our high-throughput combinatorial platform for nanoparticle fabrication and screening that uniquely enables Bind to develop and manufacture targeted nanoparticle therapeutics optimized for a specific disease,” remarks  Stephen Zale, Ph.D., vp of development.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »